Stem Cell Cardiac Toxicity Model for Testing Chemotherapy Agents
A team of scientists has developed a new safety index for a common group of chemotherapy drugs, by using a stem cell model to screen such therapies for their potential to damage patients’ hearts.
The study, published in Science Translational Medicine, was co-authored by Paul Burridge, PhD, assistant professor of Pharmacology.
Tyrosine kinase inhibitors (TKIs), a class of chemotherapy drugs, have become increasingly important in treating many types of cancer. But almost all TKIs are also associated with cardiovascular side effects — ranging from arrhythmias to heart failure — and there has not yet been an effective tool to predict this cardiotoxicity.
In the current study, the scientists demonstrated that human-induced pluripotent stem cells can be used to model how TKIs might affect the hearts of patients receiving chemotherapy.
To do so, the scientists took stem cells from both a control group and patients with cancer and reprogrammed them to become cardiomyocytes, or heart muscle cells. Using high-throughput screening, they then evaluated how the heart cells responded to treatment with 21 different FDA-approved TKIs, looking at factors like cell survival, signaling and alterations in their ability to beat properly.
With the stem-cell data, the scientists were able to create a “cardiac safety index,” which ranks the TKIs on their likelihood of inflicting heart damage. That index correlates with the toxicity that has been observed in patients clinically — a validation that suggests the screening system might be a powerful tool in predicting toxicity before therapies are ever administered to patients.
Future research could establish even more specific predictions, by comparing the genomes of patients who might experience a certain drug side effect, such as atherosclerosis, with those who don’t. “Long-term, what my lab is interested in is taking a patient’s whole genome and, based on the work we’ve done in the past, being able to predict whether a patient will have an adverse drug event,” said Burridge, also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “This is the whole idea of pharmacogenomics, or precision medicine: Everyone is going to have a different response to a drug, and that response — good or bad — is already encoded in all of us.”
In the study, the scientists also discovered that administering insulin or insulin-like growth factor 1 alongside TKIs seemed to protect against some of the heart damage associated with the drugs. “While it’s still early, this is the first step toward opening up a whole new field of identifying cardioprotectants to reduce the toxicity of these drugs,” Burridge said.
This article has been republished from materials provided by Northwestern University, Feinberg School of Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018